Literature DB >> 9612672

Chronic bronchioloalveolitis associated with human T-cell lymphotrophic virus type I infection.

M Sugimoto1, M Kitaichi, A Ikeda, S Nagai, T Izumi.   

Abstract

The lung is a preferential site for human T-cell lymphotropic virus type I infection. This peculiar tropism for the lung is responsible for the high incidence of pulmonary involvement in patients with human T-cell lymphotropic virus type I infection. A variety of pulmonary manifestations may be present in human T-cell lymphotropic virus type I-associated pulmonary diseases, but the characteristic features of this disorder appear to be chronic bronchioloalveolitis with or without fibrotic changes of surrounding parenchyma. As for the pathogenesis of pulmonary involvement associated with human T-cell lymphotropic virus type I infection, immunologic mechanisms through T-cell activation may play an important role. Such attractive interpretations need further verification.

Entities:  

Mesh:

Year:  1998        PMID: 9612672     DOI: 10.1097/00063198-199803000-00007

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  9 in total

1.  Elevated levels of beta-chemokines in bronchoalveolar lavage fluid (BALF) of individuals infected with human T lymphotropic virus type-1 (HTLV-1).

Authors:  M Seki; J I Kadota; Y Higashiyama; K Iida; T Iwashita; E Sasaki; S Maesaki; K Tomono; S Kohno
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  Bronchoalveolar lymphocytosis correlates with human T lymphotropic virus type I (HTLV-I) proviral DNA load in HTLV-I carriers.

Authors:  S Mori; A Mizoguchi; M Kawabata; H Fukunaga; K Usuku; I Maruyama; M Osame
Journal:  Thorax       Date:  2005-02       Impact factor: 9.139

3.  Diffuse panbronchiolitis after humanized anti-CCR4 monoclonal antibody therapy for relapsed adult T-cell leukemia/lymphoma.

Authors:  Koji Kato; Toshihiro Miyamoto; Akihiko Numata; Takashi Nakaike; Hideyo Oka; Ayano Yurino; Takuro Kuriyama; Yasuo Mori; Satoshi Yamasaki; Tsuyoshi Muta; Katsuto Takenaka; Hiromi Iwasaki; Takanori Teshima; Koichi Akashi
Journal:  Int J Hematol       Date:  2013-02-09       Impact factor: 2.490

4.  Effectiveness of Combined Therapy with Pirfenidone and Erythromycin for Unclassifiable Interstitial Pneumonia Induced by HTLV-1-associated Bronchioloalveolar Disorder (HABA).

Authors:  Naoko Yokohori; Akitoshi Sato; Mizue Hasegawa; Hideki Katsura; Kenzo Hiroshima; Tamiko Takemura
Journal:  Intern Med       Date:  2017-01-01       Impact factor: 1.271

Review 5.  Human T-cell leukaemia virus type 1 associated pulmonary disease: clinical and pathological features of an under-recognised complication of HTLV-1 infection.

Authors:  Lloyd Einsiedel; Fabian Chiong; Hubertus Jersmann; Graham P Taylor
Journal:  Retrovirology       Date:  2021-01-06       Impact factor: 4.602

6.  Human T-Cell Leukemia Virus Type 1 Changes Leukocyte Number and Oxidative Stress in the Lung and Blood of Female BALB/c Mice.

Authors:  Mahdiyeh Hedayati-Moghadam; S A Rahim Rezaee; Mohammad Hossein Boskabady; Nema Mohamadian Roshan; Saeideh Saadat; Kowsar Bavarsad; Saeed Niazmand
Journal:  Adv Biomed Res       Date:  2021-01-30

7.  Pulmonary function testing in HTLV-I and HTLV-II infected humans: a cohort study.

Authors:  Edward L Murphy; Helen E Ownby; James W Smith; George Garratty; Sheila T Hutching; Ying Wu; Dannie I Ameti
Journal:  BMC Pulm Med       Date:  2003-07-28       Impact factor: 3.317

Review 8.  Human T Lymphotropic Virus Type I (HTLV-I) Oncogenesis: Molecular Aspects of Virus and Host Interactions in Pathogenesis of Adult T cell Leukemia/Lymphoma (ATL).

Authors:  Sanaz Ahmadi Ghezeldasht; Abbas Shirdel; Mohammad Ali Assarehzadegan; Tahereh Hassannia; Hosian Rahimi; Rahele Miri; S A Rahim Rezaee
Journal:  Iran J Basic Med Sci       Date:  2013-03       Impact factor: 2.699

Review 9.  Role of Viral Infections in the Pathogenesis of Sjögren's Syndrome: Different Characteristics of Epstein-Barr Virus and HTLV-1.

Authors:  Hideki Nakamura; Toshimasa Shimizu; Atsushi Kawakami
Journal:  J Clin Med       Date:  2020-05-13       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.